Association Between Ipilimumab and Celiac Disease

Gentile, Nicole; D’Souza, Anita; Fujii, Larissa L.; Wu, Tsung Teh; Murray, Joseph A.

doi:10.1016/j.mayocp.2013.01.015

Cited by 57 publications

(44 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, coeliac disease serology was negative and patients did not respond to a gluten-free diet, meaning that olmesartan does not trigger coeliac disease, as observed with interferon 23 and ipilimumab. 24 Rather, olmesartan-associated enteropathy appears as a separate immune-mediated entity. Firstly, a past history of autoimmunity or inflammatory disorders is frequent.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

175

171

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Symptoms appeared 49 months [0-114] after olmesartan prescription and went on for 10 months [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. All patients had diarrhoea, three had abdominal pain and one had vomiting.…”

Section: Outcomementioning

confidence: 99%

Olmesartan-associated enteropathy: results of a national survey

Marthey

Cadiot

Seksik

et al. 2014

Aliment Pharmacol Ther

175

171

View full text Add to dashboard Cite

show abstract

“…17 This drug commonly causes gastrointestinal toxicity including enterocolitis 18 and in one case report, caused severe diarrhea that ultimately led to a new diagnosis of CD. 19 While it is not known whether ipilimumab triggered the development of CD or merely exacerbated a subclinical form of this condition, the shared immune basis of CD and CMM prompted us to investigate the relationship between these two illnesses.…”

Section: Discussionmentioning

confidence: 99%

Risk of cutaneous malignant melanoma in patients with celiac disease: A population-based study

Lebwohl

Eriksson

Hansson

et al. 2014

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background Celiac disease (CD) carries an increased risk of several malignancies, including cancers of the gastrointestinal tract and hematologic malignancies. The disease course of cutaneous malignant melanoma (CMM) is affected by the immune status of the host, and therefore may be associated with CD. Objective to test for an association between CD and CMM in a population-based setting. Methods We queried all (n=28) pathology departments in Sweden and identified patients with intestinal histology consistent with CD. Each patient was matched to up to five controls, by age, gender, calendar period, and region. Using Cox proportional hazards, we tested for an association between CD and the subsequent diagnosis of CMM. Results Among patients with CD (n=29,028), 78 subsequently developed CMM (0.3%). Compared to controls there was no significant association between CD and CMM (HR 0.94; 95%CI 0.73–1.20). This null association was similar for men (HR 0.99; 95%CI 0.68–1.44) and women (HR 0.89; 95%CI 0.64–1.24), and in all age strata. Limitations Lack of data regarding undiagnosed CD. Conclusion In this population-based study we found no association between CD and the subsequent diagnosis of CMM. Prior studies showing a positive association between these two entities may have been due to referral bias.

show abstract

“…These include some newer bio-pharmaceutical agents that can sometimes cause reversible sprue-like intestinal changes, including NSAIDs (eg., sulindac) [8] and, other drugs like olmesarten [9]. In addition, clinically occult celiac disease has appeared after use of novel biological monoclonal agents (eg., ipilimumab) [10]. Finally, in recent decades, a true increase in celiac disease per se may have occurred.…”

Section: Celiac Diseasementioning

confidence: 99%

Sprue-like Intestinal Disease

Freeman¹

2016

IJCD

View full text Add to dashboard Cite

Recurrent symptoms in well-established celiac disease may result in further clinical evaluation. In most, poor diet compliance is present. Other considerations include an unidentified gluten source, an erroneous initial diagnosis, another or second and superimposed cause for symptoms, or a complication, including collagenous sprue or an intestinal lymphoma. Failure to define an initial gluten-free diet response, however, suggests that celiac disease may not be present. Instead, a distinctive enteropathic process, refractory to diet restrictions, including gluten, is evident. This "sprue-like" intestinal disorder or enteropathy remains unclassified, and probably, represents a heterogeneous entity. Molecular changes suggestive of early clonal expansion of an aberrant population of intraepithelial lymphocytes may be detected in some (with or without a prior gluten-free diet response), and these changes may signify an early or "cryptic" lymphoma. Other newly recognized lymphoproliferative disorders occurring in the setting of celiac disease have been recorded, including hepatosplenic delta-gamma T-cell lymphoma, an indolent CD4+ T-cell lymphoma, particularly in younger males, and large granular lymphocytic leukemia, a possibly treatable disorder characterized by the clonal expansion of T-cells in blood and small intestinal mucosa. Studies using IL-15 blockade in a transgenic mouse model with pathologic features of a sprue-like intestinal disease has led to human clinical trials with encouraging positive results.

show abstract

Association Between Ipilimumab and Celiac Disease

Cited by 57 publications

References 7 publications

Olmesartan-associated enteropathy: results of a national survey

Olmesartan-associated enteropathy: results of a national survey

Risk of cutaneous malignant melanoma in patients with celiac disease: A population-based study

Sprue-like Intestinal Disease

Contact Info

Product

Resources

About